Sequential therapy of metastatic urothelial cancer with monomethyl auristatin E (MMAE)-containing antibody-drug conjugates for different targets.

IF 3.1 4区医学 Q3 ONCOLOGY

Tumori Pub Date : 2025-09-29 DOI:10.1177/03008916251362021

Jiaping Yang, Zhenxia Ma, Weiqin Sun, Mingjuan Sun, Sheng Zhang

引用次数: 0

Abstract

Introduction: Antibody-drug conjugate (ADC) has become the standard of treatment for metastatic urothelial cancer. Current trials generally test the combination or sequential use of antibody-drug conjugates with different targets and different chemotherapeutic reagents.

Case description: We show that in three patients with metastatic urothelial cancer who have progressed on anti-HER2 antibody-drug conjugates, two showed responses when treated with EV (the same monomethyl auristatin E-containing ADC, but with different targets).

Conclusion: This result showed the therapeutic potential of sequential use of ADC containing the same chemotherapeutic reagents with different targets for metastatic urothelial cancer.

查看原文本刊更多论文

转移性尿路上皮癌序贯治疗不同靶点含单甲耳素E （MMAE）的抗体-药物偶联物

抗体-药物偶联（ADC）已成为转移性尿路上皮癌的标准治疗方法。目前的试验通常测试不同靶点和不同化疗试剂的抗体-药物偶联物的组合或顺序使用。病例描述：我们研究了3例在抗her2抗体-药物偶联治疗中进展的转移性尿路上皮癌患者，其中2例在使用EV（同一种含单甲基耳抑素e的ADC，但具有不同的靶点）治疗时显示出应答。结论：本研究结果表明，连续使用含有不同靶点的相同化疗药物的ADC治疗转移性尿路上皮癌具有治疗潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Tumori 医学-肿瘤学

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

6 months

期刊介绍： Tumori Journal covers all aspects of cancer science and clinical practice with a strong focus on prevention, translational medicine and clinically relevant reports. We invite the publication of randomized trials and reports on large, consecutive patient series that investigate the real impact of new techniques, drugs and devices inday-to-day clinical practice.